European Orphan Status Granted to Bayer and Onyx Drug
Posted on: Wednesday, 19 April 2006, 21:01 CDT
Bayer Pharmaceuticals' and Onyx Pharmaceuticals' Nexavar tablets has been granted orphan medicinal product status by the European Commission for the treatment of liver cancer.
This designation is based on a recommendation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA).
"This orphan medicinal product designation demonstrates the European Commission's commitment to the study and development of treatments for rare diseases," said Dr Susan Kelley, vice president of oncology at Bayer Pharmaceuticals. "This support adds momentum to our research efforts with Nexavar and brings hope of a new treatment option to liver cancer patients in Europe."
At the 16th American Association for Cancer Research meeting in 2004, investigators reported that, in a phase II single agent study, 43% of patients treated with Nexavar experienced stable disease for at least four months and an additional 9% of patients experienced tumor shrinkage.
A phase III trial of Nexavar administered as a single agent is ongoing. The study is designed to measure differences in overall survival, time-to- symptom progression and time-to-tumor progression (TTP) of Nexavar versus placebo in liver cancer patients. A randomized phase II trial for liver cancer patients to evaluate the efficacy of Nexavar in combination with the chemotherapeutic agent doxorubicin is also ongoing.
Source: Datamonitor
Related Articles
- Hyperion Therapeutics Announces Results of Phase I Study in Patients With Liver Cirrhosis
- Frost & Sullivan to Host Analyst Briefing on the European Orphan Diseases Market: Niche-Busters - An Attractive Future?
- Sucampo Pharmaceuticals Initiates Phase 2 Trial of Cobiprostone for the Treatment of Portal Hypertension in Patients With Liver Cirrhosis
- Latest Most Up-to-Date Cancer Personalized Medicine Market Report
- St. Jude Medical Announces First Patient Implants in Clinical Study Evaluating Deep Brain Stimulation for Depression
- Cogentus Enrolls First European Patient in Phase III Study of Combination Drug
- Aspect Medical Systems to Host Conference Call to Discuss New England Journal of Medicine Study on Anesthesia Awareness and the Bispectral Index
- Fralex Reaches 100th Patient Milestone in Fibromyalgia Study
- View Scientific Rationale for Novel Therapeutics in Lung Cancer, And the Results of Clinical Trials to Date Inside 'Triple Analysis: Non Small Cell Lung Cancer, Protein Kinase Inhibitors & Anti-Angiogenic Agents'
- Colon-Tested Patients Cancer-Free at 5 Yrs
 |
 |
User Comments (0)
RSS Feeds